Venous thromboembolism (VTE) is a common and serious medical complication among medical and surgical patients, both in the hospital and postdischarge. Patients with venous stasis or vascular damage or those with underlying hypercoagulable disorders, including cancer, are at risk of developing VTE. The clinical consequences of inadequate treatment of VTE can result in significant patient morbidity and mortality. The direct health care costs and indirect societal costs related to VTE and its complications are high. Traditional anticoagulants can reduce recurrent VTE but they present costly management challenges. Oral anticoagulants currently in development offer simpler management compared with the established agents, potentially resulting in improved adherence with VTE treatment regimens and better outcomes. Reductions in recurrent VTE and its associated complications could translate into reduced direct and indirect costs.
Keywords: anticoagulants; direct Xa inhibitor; direct thrombin inhibitor; pharmacoeconomics; venous thromboembolism.